摘要
背景:covid-19老年人口的死亡率以惊人的速度增长,76岁以上人群的死亡率为18%。欧盟和美国主要由于缺乏选择性免疫和抗sarsCo-V-2治疗而表现出更高的死亡率。关于covid-19对老年人群的影响和氨基喹啉治疗失败的报道非常有限。 方法:我们在PubMed/Medline数据库中进行了大量的文献回顾,以提取有关covid-19对欧盟、中国、美国covid-19患者老年人群的影响和近期氨基喹啉治疗失败的信息,以及接种疫苗的要求。 结果和讨论:SARSCo-V-2的亲本菌株和突变体由于免疫能力低,均可导致老年人严重的呼吸并发症、多器官衰竭和凝血异常。氨基喹啉衍生物,如氯喹(CQ)和羟基氯喹(HCQ),主要是用于covid-19治疗的首选,但在世界范围内对其使用存在一些争议。本文综述了covid-19对欧盟老年人群的影响,以及氨基喹啉类药物的作用机制。此外,如果covid-19患者已经存在糖尿病和高血压等并发症,那么CQ和HCQ并不是首选的药物选择。 结论:在欧盟、中国和美国患者中,核酸疫苗、蛋白亚单位疫苗、病毒载体疫苗、灭活疫苗等新型疫苗用于治疗氨基喹啉治疗失败后的SARS-CoV-2感染。然而,其中一些疫苗尚未对来自英国、尼日利亚、南非、巴西和印度的SARSCoV-2突变株进行检测。
关键词: 老年人群、氨基喹啉治疗、CQ、HCQ、SARSCoV-2、药理学、临床研究。
Current Medicinal Chemistry
Title:COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19
Volume: 29 Issue: 20
关键词: 老年人群、氨基喹啉治疗、CQ、HCQ、SARSCoV-2、药理学、临床研究。
摘要:
Background: Mortality of the older adult population suffering from COVID-19 has been increasing at an alarming rate, and people older than 76 years of age reported 18% mortality. Mainly, the EU and USA exhibited a greater fatality rate due to lack of selective immunization and anti-SARS Co-V-2 therapeutics. Very limited reports are available to delineate the impact of COVID-19 on the geriatric population and the failures of aminoquinoline therapy.
Methods: We performed a substantial literature review in the PubMed/Medline databases to extract the information pertaining to the COVID-19 impact on the geriatric population and recent failures of aminoquinoline therapy in COVID-19 patients of EU, China, USA and the requirement of vaccination.
Results and Discussions: Both parental strains and mutant variants of SARS Co-V-2 can induce severe respiratory complications, multiorgan failure, and clotting abnormalities in older adults due to low immunocompetence. Aminoquinoline derivatives, such as chloroquine (CQ) and hydroxychloroquine (HCQ), are preferred primarily for COVID-19 treatment, but several controversies are being reported for its usage worldwide. In this review, we have provided the effects of COVID-19 on the geriatric population of EU and an overview of the mechanism of action of aminoquinolines. Furthermore, CQ and HCQ are not the preferred choice of drugs if the COVID-19 patients already have existing co-morbid conditions viz., diabetes mellitus and hypertension.
Conclusion: A new advent of COVID-19 vaccines, such as nucleic acid-based (DNA/mRNA) vaccines, protein subunit vaccines, viral vector vaccines, and inactivated vaccines, have been developed for treating SARS-CoV-2 infection after the failure of aminoquinoline therapy in EU, China, and USA patients. However, some of the vaccines are yet to be examined against mutant strains of SARS CoV-2 that originated in the UK, Nigeria, South Africa, Brazil, and India.
Export Options
About this article
Cite this article as:
COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19, Current Medicinal Chemistry 2022; 29 (20) . https://dx.doi.org/10.2174/0929867329666220301113146
DOI https://dx.doi.org/10.2174/0929867329666220301113146 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Interstitial Lung Disease in Rheumatoid Arthritis
Current Rheumatology Reviews Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Preface
Current Medicinal Chemistry Synthetic Peptides As Non-Viral DNA Vectors
Current Gene Therapy Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Kallikrein-Kinin System Mediated Inflammation in Alzheimers Disease In Vivo
Current Alzheimer Research LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Nitrergic Response to Clostridium perfringens Infection in the Rat Brain Regions Effect of Red Light Irradiation
Central Nervous System Agents in Medicinal Chemistry Conformer Profiles and Biological Activities of Peptides
Current Organic Chemistry Patent Selections
Recent Patents on Biomarkers Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies
Current Pharmaceutical Design 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews Microsponge Delivery System
Current Drug Delivery The Properties of Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) and its Applications in Tissue Engineering
Current Stem Cell Research & Therapy Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses)
Current Pharmaceutical Design